Newswise — ORLANDO, Fla. — Cancer Discovery, the newest journal in the robust publication program of the American Association for Cancer Research, will debut at the AACR 102nd Annual Meeting 2011, held here from April 2-6.
The debut sample issue will feature research that enhances the classification of prostate cancer and proposes a possible new therapy, introduces potential new targets for lung cancer, and redefines immunotherapy in breast cancer.
Co-editors in Chief Lewis Cantley, Ph.D., director of the Beth Israel Deaconess Medical Center and professor of Systems Biology at Harvard Medical School, and Jose Baselga, M.D., Ph.D., associate director and chief of the division of hematology/oncology at the Massachusetts General Hospital, will host a press conference on these studies and discuss the implications of the new journal for the field. This press conference will be held on Sunday, April 3 at 1:00 p.m. ET in Room W313 of the Orange County Convention Center.
“Cancer Discovery is poised to make major contributions to the growing body of knowledge. These papers are examples of the practice-changing research we can expect from this esteemed journal,” said Cantley.
Reporters who cannot attend the press conference in person can participate by using the following information:
• U.S. & Canada: (888) 647-7462 • International: (201) 604-0169• Access Code: 244088
The following research will be presented during the AACR press conference:
• Scientists Identify KRAS Rearrangements in Metastatic Prostate Cancer• New Target Identified for Squamous Cell Lung Cancer
Press registration for the AACR 102nd Annual Meeting 2011 is free to qualified journalists and public information officers: http://www.aacr.org/PressRegistration
Follow the AACR on Twitter: @AACR #AACRFollow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 32,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.
RSS